in vivo News and Research

RSS

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

A recent study under review at Nature Portfolio and posted to the Research Square* preprint server depicted how cellular nucleic acid-binding protein (CNBP) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

3 May 2022

Multi-omics identify COVID-19 severity predictors and prothrombotic signatures in patients with end-stage kidney disease

Researchers demonstrated that plasma levels of leucine-rich repeat-containing 15 are a strong indicator of the severity of COVID-19 in patients with end-stage kidney disease.

3 May 2022

Efficacy of affinity resin containing Galanthus nivalis agglutinin against SARS-CoV-2

A new study demonstrated the efficacy of the Galanthus nivalis agglutinin (GNA)-incorporated affinity resin against various SARS-CoV-2 variants.

3 May 2022

Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2

A new study analyzed multivalent messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine constructs against certain β-coronaviruses (β-CoVs).

3 May 2022

One step solvothermal synthesis of pure red emissive carbon dots from citric acid and urea in formic acid

Carbon dots (CDs) are a kind of zero-dimensional carbonaceous nanomaterial. Due to their ultra-small size (usually less than 10 nm), simple synthesis, low toxicity, well-documented biocompatibility, and outstanding luminescent properties, CDs have attracted wild applications, particularly in bioimaging and biomedical fields.

3 May 2022

The generation of SARS-CoV-2 virus-like particles in insect cells

Researchers have reported the development of a promising COVID-19 vaccine candidate which is based on SARS-CoV-2 VLPs, derived from the co-expression of the spike, membrane, and envelope structural proteins in the baculovirus expression system.

2 May 2022

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

A recent research paper posted to the bioRxiv* preprint server demonstrated that a cocktail of two synergetic antibodies extensively neutralized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including Omicron BA.1 and BA.2.

1 May 2022

Probenecid shows activity against respiratory syncytial virus

A new study describes the antiviral activity of the approved drug probenecid against respiratory syncytial virus.

29 Apr 2022

Study reveals new approach for engineering stable articular cartilage

A new study assesses the effect of the gremlin-1 (GREM1) protein on the in vitro and in vivo stability of bone marrow stem cell (BMSC)-derived cartilage engineered within scaffolds.

29 Apr 2022

Study illustrates how a protein complex controls genome organization to maintain lineage fidelity

Understanding the molecular mechanisms that specify and maintain the identities of more than 200 cell types of the human body is arguably one of the most fundamental problems in molecular and cellular biology, with critical implications for the treatment of human diseases. Central to the cell fate decision process are stem cells residing within each tissue of the body.

29 Apr 2022

Artificial circular RNAs found to bypass cellular antiviral responses

Researchers produced artificial circular ribonucleic acid sponges in a permuted intron-exon system and showed that these did not activate innate immunity.

29 Apr 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Evaluating nano alum as a substitute for conventional alum-based vaccine adjuvant

Researchers evaluated the performance and safety of nano alum adjuvant as next-generation coronavirus disease 2019 (COVID-19) vaccine antigens.

28 Apr 2022

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

A new review initially described the developments in cancer-based medicines that included vaccinations, vector-based techniques, and genome injection using DNA and RNA-based nucleic acid therapeutics.

28 Apr 2022

Cellular reprogramming can lead to better liver tissue regeneration in mice

Mammals can't typically regenerate organs as efficiently as other vertebrates, such as fish and lizards. Now, Salk scientists have found a way to partially reset liver cells to more youthful states - allowing them to heal damaged tissue at a faster rate than previously observed.

27 Apr 2022

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery.

From CN Bio 26 Apr 2022

Recipients for the 2022 NCCN Foundation Young Investigator Awards Program announced

The National Comprehensive Cancer Network and the NCCN Foundation today announced seven recipients for the 2022 NCCN Foundation Young Investigator Awards (YIA) Program.

25 Apr 2022

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

A recent review paper, published in the MDPI’s specialized journal COVID, highlights key features of the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – and examines the potential and roadblocks in using renewable marine resources in the fight against the coronavirus disease 2019 (COVID-19).

24 Apr 2022

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Researchers isolate three mAbs that broadly neutralized sarbecoviruses and carried out virological and structural studies of these mAbs.

21 Apr 2022

Intranasal nanoparticle STING agonist with immunoantiviral activity against SARS-CoV-2 variants

Researchers developed an immunoantiviral, NanoSTING, and demonstrated its broad-spectrum antiviral properties in hamsters and mice.

21 Apr 2022

in vivo News and Research

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

Multi-omics identify COVID-19 severity predictors and prothrombotic signatures in patients with end-stage kidney disease

Efficacy of affinity resin containing Galanthus nivalis agglutinin against SARS-CoV-2

Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2

One step solvothermal synthesis of pure red emissive carbon dots from citric acid and urea in formic acid

The generation of SARS-CoV-2 virus-like particles in insect cells

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

Probenecid shows activity against respiratory syncytial virus

Study reveals new approach for engineering stable articular cartilage

Study illustrates how a protein complex controls genome organization to maintain lineage fidelity

Artificial circular RNAs found to bypass cellular antiviral responses

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Evaluating nano alum as a substitute for conventional alum-based vaccine adjuvant

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

Cellular reprogramming can lead to better liver tissue regeneration in mice

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

Recipients for the 2022 NCCN Foundation Young Investigator Awards Program announced

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Intranasal nanoparticle STING agonist with immunoantiviral activity against SARS-CoV-2 variants

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News